Sunday, October 17, 2021

Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS

CARLSBAD, Calif., Oct. 17, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with...



from PR Newswire: https://ift.tt/3pc1s5y

No comments:

Post a Comment